Another study reported that LBP (i.g., 10 mg/kg) intervention reduced liver wet weight in non-alcoholic fatty liver disease (NAFLD) rats, lowered mRNA expression levels of fibrosis markers collagen 1 (Col-I), Col-III, and α-SMA, and decreased the expression of inflammatory cytokines IL-1β, TGF-β1, and IL-6 in serum. Here, ACTA1 is linked to metabolic dysfunction-associated steatotic liver disease.